PT - JOURNAL ARTICLE AU - Karin Leunen AU - Isabelle Cadron AU - Toon Van Gorp AU - Frédéric Amant AU - Patrick Berteloot AU - Patrick Neven AU - Eric Legius AU - Ignace Vergote TI - Does Paclitaxel-Carboplatin Chemotherapy in a Dose-Dense Regimen Enhance Survival of <em>BRCA</em>-Related Ovarian Cancer Patients? AID - 10.1111/IGC.0b013e3181bb703f DP - 2009 Nov 01 TA - International Journal of Gynecologic Cancer PG - 1501--1504 VI - 19 IP - 9 4099 - http://ijgc.bmj.com/content/19/9/1501.short 4100 - http://ijgc.bmj.com/content/19/9/1501.full SO - Int J Gynecol Cancer2009 Nov 01; 19 AB - In a group of 6 BRCA-related ovarian cancer patients presenting with clinical relapse, paclitaxel-carboplatin (TC) in a dose-dense regimen was administered to evaluate the response and tolerability compared with those of the sporadic group and of the patients using a regimen administered every 3 weeks.All patients were carboplatin sensitive at the time of first relapse: 4 patients showed intermediate sensitivity (6-12 months), and 2 patients were truly carboplatin sensitive (&gt;12 months) at first relapse and first administration of a TC dose-dense regimen. A total of 14 dose-dense regimens were administered in a median 5th line (range, 2nd-10th line). A median of 2 dose-dense regimens (range, 1-4) was given per patient. After first administration of the TC dose-dense regimen (median, 3rd line), this resulted in response in all patients: complete remission in 33% and partial remission in the remaining 67%. Furthermore, after another consecutive line of TC dose-dense regimen, 100% response (75% with partial remission and 25% with complete remission) was reached.The results are encouraging and support the observation of extreme carboplatin sensitivity of BRCA-related ovarian cancer. The use of a TC dose-dense regimen might be even more effective.